ArticleBiomacromolecules2017
Polyvalent Folate-Dendrimer-Coated Iron Oxide Theranostic Nanoparticles for Simultaneous Magnetic Resonance Imaging and Precise Cancer Cell Targeting.
Article in Biomacromolecules, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 156 citations in OpenAlex.
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Designing Water-Soluble Macromolecules for Biomedical Use: PEG Chains versus Amino AcidsA Case Study in MRI Contrast Agents.ACS polymers Au · 2026Article
- Nanotechnology for reproductive healthcare: a comprehensive review.Journal of nanobiotechnology · 2026Review
- Harnessing nanomedicine to target NF-κB signalling in cancer: at the intersection of inflammatory signalling, metabolic reprogramming, and therapeutic innovation.Cell communication and signaling : CCS · 2026Review
- Development and characterization of pegylated FeScientific reports · 2025Article
- Nano-Drug Delivery Systems for Bone Metastases: Targeting the Tumor-Bone Microenvironment.Pharmaceutics · 2025Review
- Advanced Nano-Drug Delivery Systems in the Treatment of Ischemic Stroke.Molecules (Basel, Switzerland) · 2024Review
- The utilization of nanotechnology in the female reproductive system and related disorders.Heliyon · 2024Review
- New opportunities for RGD-engineered metal nanoparticles in cancer.Molecular cancer · 2023Review
- Advances in Lung Cancer Treatment Using Nanomedicines.ACS omega · 2023Review
- Nanoconstructs for theranostic application in cancer: Challenges and strategies to enhance the delivery.Frontiers in pharmacology · 2023Review
- Magnetic triazine-based dendrimer as a versatile nanocarrier for efficient antiviral drugs delivery.Scientific reports · 2022Article
- Recent advances of magnetite nanomaterials to remove arsenic from water.RSC advances · 2022Review
- Significance of Capping Agents of Colloidal Nanoparticles from the Perspective of Drug and Gene Delivery, Bioimaging, and Biosensing: An Insight.International journal of molecular sciences · 2022Review
- Application of Dendrimers in Anticancer Diagnostics and Therapy.Molecules (Basel, Switzerland) · 2022Review
- Magnetic Resonance Neuroimaging Contrast Agents of Nanomaterials.BioMed research international · 2022Article
- The Development of Nanoparticles for the Detection and Imaging of Ovarian Cancers.Biomedicines · 2021Review
- 3,4-Difluorobenzocurcumin Inhibits Vegfc-Vegfr3-Erk Signalling to Block Developmental Lymphangiogenesis in Zebrafish.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Engineered EV-Mimetic Nanoparticles as Therapeutic Delivery Vehicles for High-Grade Serous Ovarian Cancer.Cancers · 2021Review
- Functionalization of Metal and Carbon Nanoparticles with Potential in Cancer Theranostics.Molecules (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The low therapeutic index of conventional chemotherapy and poor prognosis of patients diagnosed with metastatic cancers are prompting clinicians to adopt newer strategies to simultaneously detect cancer lesions at an early stage and to precisely deliver anticancer drugs to tumor sites. In this study, we employed a novel strategy to engineer a polyvalent theranostic nanocarrier consisting of superparamagnetic iron oxide nanoparticle core (SPIONs) decorated with folic acid-polyamidoamine dendrimers surface (FA-PAMAM). In addition, a highly potent hydrophobic anticancer agent 3,4-difluorobenzylidene-curcumin (CDF) was coloaded in the FA-PAMAM dendrimer to increase its solubility and assess its therapeutic potentials. The resulting targeted nanoparticles (SPIONs@FA-PAMAM-CDF) exhibited high MR contrast. When tested on folate receptor overexpressing ovarian (SKOV3) and cervical (HeLa) cancer cells, the CDF loaded targeted nanoformulations showed higher accumulation with a better anticancer activity as compared to the nontargeted counterparts, possibly due to multivalent folate receptor binding interaction with cells overexpressing the target. The results were corroborated by observation of a larger population of cells undergoing apoptosis due to upregulation of tumor suppressor phosphatase and tensis homologue (PTEN), caspase 3, and inhibition of NF-κB in groups treated with the targeted formulations, which further confirmed the ability of the multivalent theranostic nanoparticles for simultaneous imaging and therapy of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.